TLR4 and neoplasm: Similar to divalent peptide3A5, divalent ILVIK competitively inhibited S100A8 binding to TLR4/MD-2 and inhibited tumor growth in subcutaneously transplanted SW480 cells in a dose-dependent manner (Fig. 7G).